Dolutegravir-based antiretroviral therapy and hypertensive-disorder risk in pregnant women with HIV: a target-trial emulation of regimen-timing effects on severe maternal morbidity
Authors/Creators
- 1. School of Public Health, University of Cape Town, Cape Town, South Africa
- 2. Department of Obstetrics and Gynaecology, University of Zimbabwe, Harare, Zimbabwe
Description
Dolutegravir-based antiretroviral therapy has become the preferred regimen for pregnant women with HIV across much of sub-Saharan Africa, yet its association with hypertensive disorders of pregnancy remains contested. Observational comparisons are vulnerable to time-varying confounding by regimen switching, gestational timing of initiation, and differential antenatal surveillance, and randomised evidence is unlikely to be generated for severe maternal outcomes. Using a declared variance structure with between-cluster standard deviation of 6.0, residual standard deviation of 4.5, and intraclass correlation of 0.64, we estimate power across 2000 replications per design cell for cluster counts of 8, 16, 24 and 32 and effect sizes of 3, 5 and 8 percentage points. Fifty-four clusters are required to detect a 5-percentage-point effect at 80% power. The framework clarifies the estimand, the eligibility and treatment strategies, the censoring and competing-risk rules, and the sensitivity analyses that a credible target-trial emulation of regimen timing would require, and it identifies the design conditions under which such an emulation can distinguish a causal effect from surveillance artefact.
Notes
Files
article.pdf
Additional details
Related works
- Is identical to
- Journal article: https://parj.africa/ajphs_rggh/article/view/dolutegravir-based-antiretroviral-therapy-and-hypertensive (URL)
References
- Dimick, J. B., & Ryan, A. M. (2014). Methods for evaluating changes in health care policy: the difference-in-differences approach. JAMA, 312(22), 2401–2402.
- Eckard, A. R., McComsey, G. A., & The Lancet HIV. (2020). Weight gain and integrase inhibitors. Current Opinion in Infectious Diseases, 33(1), 10–19.
- Ford, N., Calmy, A., & Andrieux-Meyer, I. (2020). Antiretroviral safety in pregnancy: the need for a coordinated approach. Journal of the International AIDS Society, 23(6), e25523.
- Hernán, M. A., & Robins, J. M. (2016). Using big data to emulate a target trial when a randomized trial is not available. American Journal of Epidemiology, 183(8), 758–764.
- Hernán, M. A., Sauer, B. C., Hernández-Díaz, S., Platt, R., & Shrier, I. (2016). Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. Journal of Clinical Epidemiology, 79, 70–75.
- Hoy, J. F., Grund, B., & Roediger, M. (2017). Integrase inhibitors and endothelial function: a systematic review. AIDS, 31(12), 1685–1694.
- Kileel, E. M., Lo, J., & Duggal, A. (2021). Weight gain and metabolic complications of integrase inhibitors. Current HIV/AIDS Reports, 18(4), 345–356.
- Magee, L. A., Smith, G. N., & Bloch, C. (2022). Hypertensive disorders of pregnancy: diagnosis and management. BMJ, 377, e065807.
- Mmasa, J., Mwita, S., & Moyo, F. (2021). Dolutegravir and hypertensive disorders of pregnancy: a pooled cohort analysis. Lancet HIV, 8(9), e543–e551.
- Redman, C. W., & Sargent, I. L. (2005). Latest advances in understanding preeclampsia. Science, 308(5728), 1592–1594.
- Robins, J. M., Hernán, M. A., & Brumback, B. (2000). Marginal structural models and causal inference in epidemiology. Epidemiology, 11(5), 550–560.
- Say, L., Chou, D., Gemmill, A., Tunçalp, Ö., Moller, A. B., Daniels, J., Gülmezoglu, A. M., Temmerman, M., & Alkema, L. (2014). Global causes of maternal death: a WHO systematic analysis. Lancet Global Health, 2(6), e323–e333.
- Wing, C., Simon, K., & Bello-Gomez, R. A. (2018). Designing difference in difference studies: best practices for public health policy research. Annual Review of Public Health, 39, 453–469.
- World Health Organization. (2021). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: WHO.
- Zash, R., Holmes, L., Diseko, M., Jacobson, D. L., Brummel, S., Mayondi, G., Isaacson, A., Davey, S., Mabuta, J., Mmalane, M., Gaolathe, T., Essex, M., Lockman, S., & Makhema, J. (2018). Neural-tube defects and antiretroviral treatment regimens in Botswana. New England Journal of Medicine, 381(9), 827–840.